{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:15:17Z","timestamp":1788826517954,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine","award":["ZYYCXTD-C-202010"],"award-info":[{"award-number":["ZYYCXTD-C-202010"]}]},{"name":"Scientific Research Special Fund of Traditional Chinese Medicine Industry","award":["201407001-12"],"award-info":[{"award-number":["201407001-12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In this study, Chinese herbal compound prescriptions combined with Chinese medicine powder were evaluated for the treatment of chronic atrophic gastritis with erosion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multi-center, randomized, positive drug control clinical trial randomly assigned 216 patients with chronic atrophic gastritis with erosion to three groups: (1) control group: aluminum plus magnesium suspension thrice per day for 4\u00a0weeks; (2) test group 1: Chinese herbal compound prescriptions twice a day plus Sanqi (<jats:italic>Panax notoginseng<\/jats:italic>) powder twice a day for 4\u00a0weeks; (3) test group 2: Chinese herbal compound prescriptions twice a day plus Sanqi (<jats:italic>Panax notoginseng<\/jats:italic>) powder and Zhebeimu (<jats:italic>Fritillaria thunbergii Miq<\/jats:italic>.) powder twice a day for 4\u00a0weeks. The primary endpoint (improvement of gastric mucosal erosion; improvement of gastric mucosal pathology) and secondary endpoints (improvement of clinical symptoms scores; improvement of the patient-reported outcome [PRO] instrument for chronic gastrointestinal diseases) were assessed using endoscopy at week 4 following the treatment. Drug-related adverse events (AEs) and adverse drug reactions (ADRs) were also compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The final analysis included 202 patients (control group, 63; test group 1, 69; test group 2, 70). At week 4, using within-group comparison, gastric mucosal erosion improved in each group following treatment with a significant difference (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05); there were no statistically significant differences in gastric mucosal erosion scores among the groups after treatment (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); in terms of improvement of gastric mucosal erosion, the efficacy rate of the control group was 69.12%, the efficacy rate of the test group 1 was 73.24%, and the efficacy rate of the test group 2 was 69.01% and efficacy rate among the groups was not statistically significant (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). As determined by acute inflammation, chronic inflammation, atrophy, intestinal metaplasia, and dysplasia, the pathological score (total score and the highest score) did not differ statistically among groups following treatment (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); within the control group, the total scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but there was no significant improvement in dysplasia (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); in the test group 1, chronic inflammation, atrophy, and intestinal metaplasia and dysplasia scores were significantly decreased (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but acute inflammation did not improve (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); there was a significant reduction in the atrophy score in test group 2 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but no improvement in the scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Similarly, within the control group, the highest scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but there was no significant improvement in dysplasia (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); there was a significant reduction in highest scores of atrophy, intestinal metaplasia, and dysplasia (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) in test group 1, but the highest scores didn\u2019t not improve with acute inflammation and chronic inflammation (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05); there was a significant reduction in the highest atrophy score in test group 2 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but no improvement in the highest scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Compared to the control group, the main symptom scores and total symptom scores in the test groups were lower following treatment, with a statistically significant difference (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05); the analysis of covariance with center, erosion type, and group as factors was applied, and the comparison among the groups in dyspepsia, defecation, and total PRO instrument scores were statistically significant (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). In the study period, AEs were reported in 3 (4.23%) patients in the test group 1 and 3 (4.41%) patients in the control group; ADRs were confirmed in 3 (4.23%) patients from the test group 1 and 2 (2.94%) from the control group. AEs and ADRs were not statistically significantly different among groups (AE, <jats:italic>P<\/jats:italic>\u2009=\u20090.2213; ADR, <jats:italic>P<\/jats:italic>\u2009=\u20090.2872). No serious AE or ADR was reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study has shown that both aluminum plus magnesium suspension and Chinese herbal compound prescriptions together with <jats:italic>Panax notoginseng<\/jats:italic> powder are capable of improving gastric mucosal erosion and reducing gastric mucosal pathological scores, and there were no statistically significant differences among the groups in primary endpoints, indicating that Chinese herbal therapy can achieve similar efficacy than antacids in terms of primary outcomes. The aluminum plus magnesium suspension is comparable to Chinese herbal therapy in improving atrophy and intestinal metaplasia, and is inferior to Chinese herbal therapy in improving dysplasia. In addition, the Chinese herbal therapy significantly outperforms the aluminum plus magnesium suspension in improving symptoms. Therefore, the overall clinical outcome of Chinese herbal compound prescriptions together with <jats:italic>Panax notoginseng<\/jats:italic> powder based on TCM syndrome patterns in the treatment of erosive gastritis is superior to that of antacids.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ChiCTR, ChiCTR-IPR-15005905. Registered 22 January 2015, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/showproj.aspx?proj=10359\">https:\/\/www.chictr.org.cn\/showproj.aspx?proj=10359<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13020-022-00692-7","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:02:57Z","timestamp":1671692577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Tai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoju","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"6","key":"692_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00365521.2015.1019918","volume":"50","author":"P Sipponen","year":"2015","unstructured":"Sipponen P, Maaroos HI. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657\u201367. https:\/\/doi.org\/10.3109\/00365521.2015.1019918.","journal-title":"Scand J Gastroenterol"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"S373","DOI":"10.1016\/S1590-8658(11)60593-8","volume":"43","author":"M Rugge","year":"2011","unstructured":"Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, Di Mario F, Gruppo Italiano Patologi Apparato Digerente (GIPAD), Societ\u00e0 Italiana di Anatomia Patologica e Citopatologia Diagnostica\/International Academy of Pathology, Italian division (SIAPEC\/IAP). Gastritis: the histology report. Dig Liver Dis. 2011;43:S373\u201384. https:\/\/doi.org\/10.1016\/S1590-8658(11)60593-8.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"692_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0016-5107(83)72493-4","volume":"29","author":"R Cheli","year":"1983","unstructured":"Cheli R, Giacosa A. Chronic atrophic gastritis and gastric mucosal atrophy\u2013one and the same. Gastrointest Endosc. 1983;29(1):23\u20135. https:\/\/doi.org\/10.1016\/s0016-5107(83)72493-4.","journal-title":"Gastrointest Endosc"},{"key":"692_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/758397","volume":"2010","author":"B Dewan","year":"2010","unstructured":"Dewan B, Balasubramanian A. Troxipide in the management of gastritis: a randomized comparative trial in general practice. Gastroenterol Res Pract. 2010;2010: 758397. https:\/\/doi.org\/10.1155\/2010\/758397.","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"692_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0016-5107(73)73979-1","volume":"19","author":"C Sugawa","year":"1973","unstructured":"Sugawa C, Lucas CE, Rosenberg BF, Riddle JM, Walt AJ. Differential topography of acute erosive gastritis due to trauma or sepsis, ethanol and aspirin. Gastrointest Endosc. 1973;19(3):127\u201330. https:\/\/doi.org\/10.1016\/s0016-5107(73)73979-1.","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"692_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/s0016-5107(95)70043-9","volume":"42","author":"L Laine","year":"1995","unstructured":"Laine L, Cohen H, Sloane R, Marin-Sorensen M, Weinstein WM. Interobserver agreement and predictive value of endoscopic findings for H. pylori and gastritis in normal volunteers. Gastrointest Endosc. 1995;42(5):420\u20133. https:\/\/doi.org\/10.1016\/s0016-5107(95)70043-9.","journal-title":"Gastrointest Endosc"},{"key":"692_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-230X-14-21","volume":"14","author":"Y Du","year":"2014","unstructured":"Du Y, Bai Y, Xie P, Fang J, Wang X, Hou X, Tian D, Wang C, Liu Y, Sha W, Wang B, Li Y, Zhang G, Li Y, Shi R, Xu J, Li Y, Huang M, Han S, Liu J, Ren X, Xie P, Wang Z, Cui L, Sheng J, Luo H, Wang Z, Zhao X, Dai N, Nie Y, Zou Y, Xia B, Fan Z, Chen Z, Lin S, Li ZS, Chinese Chronic Gastritis Research group. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol. 2014;14:21. https:\/\/doi.org\/10.1186\/1471-230X-14-21.","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"692_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1523-5378.2011.00871.x","volume":"16","author":"K Toljamo","year":"2011","unstructured":"Toljamo K, Niemel\u00e4 S, Karvonen AL, Karttunen R, Karttunen TJ. Histopathology of gastric erosions. Association with etiological factors and chronicity. Helicobacter. 2011;16(6):444\u201351. https:\/\/doi.org\/10.1111\/j.1523-5378.2011.00871.x.","journal-title":"Helicobacter"},{"issue":"2","key":"692_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0028-1098492","volume":"9","author":"PH Green","year":"1977","unstructured":"Green PH, Fevre DI, Barrett PJ, Hunt JH, Gillespie PE, Nagy GS. Chronic erosive (verrucous) gastritis. A study of 108 patients. Endoscopy. 1977;9(2):74\u20138. https:\/\/doi.org\/10.1055\/s-0028-1098492.","journal-title":"Endoscopy"},{"issue":"5","key":"692_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/gut.28.5.561","volume":"28","author":"M Tatsuta","year":"1987","unstructured":"Tatsuta M, Iishi H, Okuda S. Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine. Gut. 1987;28(5):561\u20135. https:\/\/doi.org\/10.1136\/gut.28.5.561.","journal-title":"Gut"},{"issue":"5","key":"692_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/den.12427","volume":"27","author":"W Hatta","year":"2015","unstructured":"Hatta W, Iijima K, Koike T, Kondo Y, Ara N, Asanuma K, Uno K, Asano N, Imatani A, Shimosegawa T. Endoscopic findings for predicting gastric acid secretion status. Dig Endosc. 2015;27(5):582\u20139. https:\/\/doi.org\/10.1111\/den.12427.","journal-title":"Dig Endosc"},{"key":"692_CR12","doi-asserted-by":"publisher","unstructured":"Fang JY, Du YQ, Liu WZ, Ren JL, Li YQ, Chen XY, Lv NH, Chen YX, Lv B; Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis. 2018 Apr;19(4):182\u2013203. doi: https:\/\/doi.org\/10.1111\/1751-2980.12593. Epub 2018 Apr 15. Erratum in: J Dig Dis. 2020 Feb;21(2):120.","DOI":"10.1111\/1751-2980.12593"},{"issue":"2","key":"692_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5056\/jnm18001","volume":"24","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182\u201396. https:\/\/doi.org\/10.5056\/jnm18001.","journal-title":"J Neurogastroenterol Motil"},{"issue":"9","key":"692_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","volume":"24","author":"M Jalving","year":"2006","unstructured":"Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24(9):1341\u20138. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03127.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"692_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2036.2005.02611.x","volume":"22","author":"AS Raghunath","year":"2005","unstructured":"Raghunath AS, O\u2019Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22(Suppl 1):55\u201363. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02611.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"692_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.5009\/gnl20036","volume":"15","author":"GH Kim","year":"2021","unstructured":"Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver. 2021;15(5):646\u201352. https:\/\/doi.org\/10.5009\/gnl20036.","journal-title":"Gut Liver"},{"issue":"1","key":"692_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","volume":"71","author":"D Abrahami","year":"2022","unstructured":"Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16\u201324. https:\/\/doi.org\/10.1136\/gutjnl-2021-325097.","journal-title":"Gut"},{"issue":"6","key":"692_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/00365521.2018.1450442","volume":"53","author":"HL Waldum","year":"2018","unstructured":"Waldum HL, S\u00f8rdal \u00d8, Fossmark R. Proton pump inhibitors (PPIs) may cause gastric cancer\u2014clinical consequences. Scand J Gastroenterol. 2018;53(6):639\u201342. https:\/\/doi.org\/10.1080\/00365521.2018.1450442.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"692_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11655-015-2114-5","volume":"22","author":"XD Tang","year":"2016","unstructured":"Tang XD, Zhou LY, Zhang ST, Xu YQ, Cui QC, Li L, Lu JJ, Li P, Lu F, Wang FY, Wang P, Bian LQ, Bian ZX. Randomized double-blind clinical trial of Moluodan () for the treatment of chronic atrophic gastritis with dysplasia. Chin J Integr Med. 2016;22(1):9\u201318. https:\/\/doi.org\/10.1007\/s11655-015-2114-5.","journal-title":"Chin J Integr Med"},{"issue":"20","key":"692_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015710","volume":"98","author":"ZX Yan","year":"2019","unstructured":"Yan ZX, Dai YK, Ma T, Lin XY, Chen WH, Liu YM, Zu RZ, Zhang XB, Jiang P, Yang JH, Li S, Zheng LS, Lin ZW. Efficacy of traditional Chinese medicine for chronic gastritis: a meta-analysis of randomized controlled trials. Medicine. 2019;98(20): e15710. https:\/\/doi.org\/10.1097\/MD.0000000000015710.","journal-title":"Medicine"},{"key":"692_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/878164","volume":"2015","author":"Y Wei","year":"2015","unstructured":"Wei Y, Ma LX, Yin SJ, An J, Wei Q, Yang JX. Huangqi Jianzhong Tang for treatment of chronic gastritis: a systematic review of randomized clinical trials. Evid Based Complement Alternat Med. 2015;2015: 878164. https:\/\/doi.org\/10.1155\/2015\/878164.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"294","key":"692_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115341","volume":"10","author":"HF Chen","year":"2022","unstructured":"Chen HF, Gong Y, Huang Z, Zhao G, Chen ZM, Zen YM, Li HZ, Hu YL. Efficacy and safety of Chinese herbal medicine Qirui Weishu capsule in treating chronic non-atrophic gastritis: a multicentre, double-blind, randomized controlled clinical trial. J Ethnopharmacol. 2022;10(294): 115341. https:\/\/doi.org\/10.1016\/j.jep.2022.115341.","journal-title":"J Ethnopharmacol"},{"issue":"7","key":"692_CR23","first-page":"44","volume":"5","author":"JY Fang","year":"2013","unstructured":"Fang JY, Liu WZ, Li ZK, Du YQ, Ji XL, Ge ZZ, et al. China Chronic Gastritis Consensus (2012, Shanghai). Chin J Front Med Sci. 2013;5(7):44\u201355.","journal-title":"Chin J Front Med Sci."},{"key":"692_CR24","first-page":"345","volume":"18","author":"SS Zhang","year":"2010","unstructured":"Zhang SS, Qg L, Tang XD, et al. Traditional Chinese medicine consensus on chronic atrophic gastritis diagnosis and treatment (2009, Shenzhen). Chin J Integr Gastroenterol. 2010;18:345\u20139.","journal-title":"Chin J Integr Gastroenterol"},{"issue":"16","key":"692_CR25","first-page":"2878","volume":"125","author":"YQ Du","year":"2012","unstructured":"Du YQ, Su T, Hao JY, Wang BM, Chen MH, Li YM, Tang CW, Gong YF, Man XH, Gao L, Cai QC, Li ZS. Gastro-protecting effect of gefarnate on chronic erosive gastritis with dyspeptic symptoms. Chin Med J. 2012;125(16):2878\u201384.","journal-title":"Chin Med J"},{"issue":"10","key":"692_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3736\/jcim20121005","volume":"10","author":"P Wang","year":"2012","unstructured":"Wang P, Tang XD, Liu BY, Zi MJ. Development of a patient-reported outcome instrument for chronic gastrointestinal diseases: item selection. Zhong Xi Yi Jie He Xue Bao. 2012;10(10):1092\u20138. https:\/\/doi.org\/10.3736\/jcim20121005 (In Chinese).","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"issue":"09","key":"692_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.16040\/j.cnki.cn15-1101.2012.09.022","volume":"31","author":"SJ Qiang","year":"2012","unstructured":"Qiang SJ, Qiang SX. Observation on therapeutic effect of chronic erosive gastritis based on syndrome differentiation. Nei Mongol J Tradit Chin Med. 2012;31(09):44. https:\/\/doi.org\/10.16040\/j.cnki.cn15-1101.2012.09.022 (In Chinese).","journal-title":"Nei Mongol J Tradit Chin Med"},{"issue":"19","key":"692_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3969\/j.issn.1672-2779.2014.19.019","volume":"12","author":"JP Huang","year":"2014","unstructured":"Huang JP, Wang JH, Tan HY, Zou WB. Baiji sanqi powder used to treat 31 cases of chronic erosive gastritis. Chin Med Modern Dist Educ China. 2014;12(19):36\u20138. https:\/\/doi.org\/10.3969\/j.issn.1672-2779.2014.19.019 (In Chinese).","journal-title":"Chin Med Modern Dist Educ China"},{"issue":"20","key":"692_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.14033\/j.cnki.cfmr.2012.20.061","volume":"10","author":"DT Zou","year":"2012","unstructured":"Zou DT. Comparison of curative effect of kangfuxin solution and aluminum plus magnesium suspension on chronic erosive gastritis. Chin Foreign Med Res. 2012;10(20):24\u20135. https:\/\/doi.org\/10.14033\/j.cnki.cfmr.2012.20.061 (In Chinese).","journal-title":"Chin Foreign Med Res"},{"issue":"12","key":"692_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005232","volume":"10","author":"Y Li","year":"2016","unstructured":"Li Y, Mei L, Qiang J, Ju S, Zhao S. Magnetic resonance spectroscopy for evaluating portal-systemic encephalopathy in patients with chronic hepatic Schistosomiasis japonicum. PLoS Negl Trop Dis. 2016;10(12): e0005232. https:\/\/doi.org\/10.1371\/journal.pntd.0005232.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"692_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1440-1746.2006.04494.x","volume":"22","author":"HJ Kim","year":"2007","unstructured":"Kim HJ, Yoo TW, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, Kim BI. Influence of overweight and obesity on upper endoscopic findings. J Gastroenterol Hepatol. 2007;22(4):477\u201381. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04494.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"692_CR32","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10620-008-0485-6","volume":"54","author":"SK Dutta","year":"2009","unstructured":"Dutta SK, Arora M, Kireet A, Bashandy H, Gandsas A. Upper gastrointestinal symptoms and associated disorders in morbidly obese patients: a prospective study. Dig Dis Sci. 2009;54(6):1243\u20136. https:\/\/doi.org\/10.1007\/s10620-008-0485-6.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"692_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/jcp.46.3.235","volume":"46","author":"GM Sobala","year":"1993","unstructured":"Sobala GM, O\u2019Connor HJ, Dewar EP, King RF, Axon AT, Dixon MF. Bile reflux and intestinal metaplasia in gastric mucosa. J Clin Pathol. 1993;46(3):235\u201340. https:\/\/doi.org\/10.1136\/jcp.46.3.235.","journal-title":"J Clin Pathol"},{"issue":"22","key":"692_CR34","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.3748\/wjg.v22.i22.5228","volume":"22","author":"TH Zou","year":"2016","unstructured":"Zou TH, Zheng RH, Gao QY, Kong X, Chen XY, Ge ZZ, Chen YX, Zou XP, Fang JY. Factors affecting occurrence of gastric varioliform lesions: a case-control study. World J Gastroenterol. 2016;22(22):5228\u201336. https:\/\/doi.org\/10.3748\/wjg.v22.i22.5228.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"692_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2036.2006.02778.x","volume":"23","author":"A Madisch","year":"2006","unstructured":"Madisch A, Miehlke S, Neuber F, Morgner A, Kuhlisch E, Rappel S, Lehn N, Bayerd\u00f6rffer E, Seitz G, Stolte M. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy\u2014a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther. 2006;23(4):473\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02778.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"692_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2021.10.036","author":"V Zimmer","year":"2022","unstructured":"Zimmer V, Emrich K. Varioliform-type lymphocytic gastritis: treating H. pylori or (rather) something else? Am J Med Sci. 2022. https:\/\/doi.org\/10.1016\/j.amjms.2021.10.036.","journal-title":"Am J Med Sci"},{"key":"692_CR37","first-page":"72","volume":"45","author":"C Munoz Monteavaro","year":"1960","unstructured":"Munoz Monteavaro C, Mendoza D, Palma E. Varioliform gastritis with \u201cin situ\u201d carcinomatous transformation. An Fac Med Univ Repub Montev Urug. 1960;45:72\u20137 (Spanish).","journal-title":"An Fac Med Univ Repub Montev Urug"},{"issue":"Suppl","key":"692_CR38","doi-asserted-by":"publisher","first-page":"AB183","DOI":"10.1016\/j.gie.2018.04.291","volume":"87","author":"H Uchima","year":"2018","unstructured":"Uchima H, Albert M, Rosales C, et al. Sa1253 verrucous gastritis might be a risk factor for early gastric neoplasia in the west. Gastrointest Endosc. 2018;87(Suppl):AB183.","journal-title":"Gastrointest Endosc"},{"issue":"29","key":"692_CR39","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.3748\/wjg.v16.i29.3664","volume":"16","author":"L Zhang","year":"2010","unstructured":"Zhang L, Hou YH, Wu K, Zhai JS, Lin N. Proteomic analysis reveals molecular biological details in varioliform gastritis without Helicobacter pylori infection. World J Gastroenterol. 2010;16(29):3664\u201373. https:\/\/doi.org\/10.3748\/wjg.v16.i29.3664.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"692_CR40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3760\/cma.j.cn311367-20210930-00524","volume":"41","author":"Gastrointestinal Hormone and Mucosal Barrier Group","year":"2021","unstructured":"Gastrointestinal Hormone and Mucosal Barrier Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus of clinical experts on gastrointestinal mucosal protection (2021, Fuzhou). Chin J Dig. 2021;41(12):798\u2013811. https:\/\/doi.org\/10.3760\/cma.j.cn311367-20210930-00524 (In Chinese).","journal-title":"Chin J Dig"},{"issue":"11","key":"692_CR41","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s10620-007-0180-z","volume":"53","author":"Y Du","year":"2008","unstructured":"Du Y, Li Z, Zhan X, Chen J, Gao J, Gong Y, Ren J, He L, Zhang Z, Guo X, Wu J, Tian Z, Shi R, Jiang B, Fang D, Li Y. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886\u201395. https:\/\/doi.org\/10.1007\/s10620-007-0180-z.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"692_CR42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF01296213","volume":"29","author":"DY Graham","year":"1984","unstructured":"Graham DY, Sackman JW, Giesing DH, Runser DJ. In vitro adsorption of bile salts and aspirin to sucralfate. Dig Dis Sci. 1984;29(5):402\u20136. https:\/\/doi.org\/10.1007\/BF01296213.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"692_CR43","first-page":"179","volume":"51","author":"BL Slomiany","year":"2000","unstructured":"Slomiany BL, Piotrowski J, Slomiany A. Up-regulation of endothelin-1 in gastric mucosal inflammatory responses to Helicobacter pylori Lipopolysaccharide: effect of omeprazole and sucralfate. J Physiol Pharmacol. 2000;51(2):179\u201392.","journal-title":"J Physiol Pharmacol"},{"issue":"2","key":"692_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/0300060514559791","volume":"43","author":"J Jin","year":"2015","unstructured":"Jin J, Li X, Xing L, Chang Y, Wu L, Jin Z, Su X, Bai Y, Zheng Y, Jiang Y, Zhao X, Lu L, Gao Q. Addition of all-trans-retinoic acid to omeprazole and sucralfate therapy improves the prognosis of gastric dysplasia. J Int Med Res. 2015;43(2):204\u201316. https:\/\/doi.org\/10.1177\/0300060514559791.","journal-title":"J Int Med Res"},{"key":"692_CR45","volume-title":"Study of TCM syndromes of chronic atrophic gastritis complicated with gastric mucosal erosion","author":"Xu Enlong","year":"2017","unstructured":"Enlong Xu. Study of TCM syndromes of chronic atrophic gastritis complicated with gastric mucosal erosion. Beijing: Beijing University of Traditional Chinese Medicine; 2017. (In Chinese)."},{"issue":"89","key":"692_CR46","first-page":"59","volume":"56","author":"L Sun","year":"2009","unstructured":"Sun L, Si J, Chen S, Liu W, Zhao L, Wang L. The establishment and clinical appliance of technique of mucosa marking targeting biopsy. Hepatogastroenterology. 2009;56(89):59\u201362.","journal-title":"Hepatogastroenterology"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-022-00692-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-022-00692-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:07:19Z","timestamp":1671692839000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-022-00692-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1186\/s13020-022-00692-7","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed following the standard of International Coordinating Committee on Global Partnerships and the revised edition of the Declaration of Helsinki. The present study was approved by the Ethic Committee of Xiyuan\u00a0Hospital\u00a0of\u00a0China\u00a0Academy\u00a0of\u00a0Chinese\u00a0Medical\u00a0Sciences (Ethical Approval Number: 2014XL091-2). It was registered in ChiCTR (ChiCTR-IPR-15005905). Every participant endorsed informed consent voluntarily.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}